Clinical Trial Update: ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

ACP-196 (acalabrutinib), a BTK inhibitor, is being studied in Phase 1/2 trials for chronic lymphocytic leukemia, Richter's syndrome, small lymphocytic lymphoma,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Prolymphocytic Leukemia
• Richter Syndrome
• Small Lymphocytic Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-09-10